Gene · 9833
Papers1,515
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,515
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of first-in-class PROTACs targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of Burkitt lymphoma. | RSC Med Chem | 2024 | 39026635 | PubTator, text mining | PubMed |
| Fusion Genes Landscape of Lung Cancer Patients From Inner Mongolia, China. | Genes Chromosomes Cancer | 2024 | 39011998 | PubTator, text mining | PubMed |
| An insight into the therapeutic effects of isoliquiritigenin in breast cancer. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | 39007925 | PubTator, text mining | PubMed |
| Correction: MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. | Signal Transduct Target Ther | 2024 | 39003278 | PubTator, text mining | PubMed |
| Deciphering the miRNA-mRNA Interaction Landscape between Breast Cancer and Triple-Negative Breast Cancer: An Integrated Bioinformatics Approach. | ACS Omega | 2024 | 38882157 | PubTator, text mining | PubMed |
| Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma. | Front Immunol | 2024 | 38863714 | PubTator, text mining | PubMed |
| DDX56 promotes EMT and cancer stemness via MELK-FOXM1 axis in hepatocellular carcinoma. | iScience | 2024 | 38827395 | PubTator, text mining | PubMed |
| Identification and validation of the TRHDE-AS1/hsa-miR-449a/ADAMTS5 axis as a novel prognostic biomarker in prostate cancer. | Biofactors | 2024 | 38818922 | PubTator, text mining | PubMed |
| miR-181a/b-5p negatively regulates keratinocytes proliferation by targeting MELK. | Arch Dermatol Res | 2024 | 38795158 | PubTator, text mining | PubMed |
| A Novel Tetramethylpyrazine Chalcone Hybrid- HCTMPPK, as a Potential Anti-Lung Cancer Agent by Downregulating MELK. | Drug Des Devel Ther | 2024 | 38737331 | PubTator, text mining | PubMed |
| Hub gene identification and immune infiltration analysis in hepatocellular carcinoma: Computational approach. | In Silico Pharmacol | 2024 | 38721057 | PubTator, text mining | PubMed |
| Targeting MELK improves PD-1 blockade efficiency in cervical cancer via enhancing antitumor immunity. | Mol Ther Oncol | 2024 | 38596298 | PubTator, text mining | PubMed |
| Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer. | Sci Rep | 2024 | 38589728 | PubTator, text mining | PubMed |
| Hsa_circ_0101050 accelerates the progression of Colon cancer by targeting the miR-140-3 p/MELK axis. | Transl Oncol | 2024 | 38579527 | PubTator, text mining | PubMed |
| Expression of circular RNA has-circ-0009158 and identification of associated miRNA-mRNA network in hepatocellular carcinoma. | Am J Transl Res | 2024 | 38463586 | PubTator, text mining | PubMed |
| The high expression of TOP2A and MELK induces the occurrence of psoriasis. | Aging (Albany NY) | 2024 | 38382096 | PubTator, text mining | PubMed |
| Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis. | Sci Rep | 2024 | 38307969 | PubTator, text mining | PubMed |
| Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma. | PLoS One | 2024 | 38306361 | PubTator, text mining | PubMed |
| New trends in diagnosis and management of gallbladder carcinoma. | World J Gastrointest Oncol | 2024 | 38292841 | PubTator, text mining | PubMed |
| Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. | Cancer Res Commun | 2024 | 38282551 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9833/papers?page=6